processes Article Labeling of Hinokitiol with 90Y for Potential Radionuclide Therapy of Hepatocellular Carcinoma Christelle Bouvry 1,2, Valérie Ardisson 1, Nicolas Noiret 3, Etienne Garin 1,4 and Nicolas Lepareur 1,4,* 1 Comprehensive Cancer Center Eugène Marquis, F-35042 Rennes, France;
[email protected] (C.B.);
[email protected] (V.A.);
[email protected] (E.G.) 2 CNRS, ISCR (Institut des Sciences Chimiques de Rennes)—UMR 6226, University Rennes, F-35000 Rennes, France 3 ENSCR, CNRS, ISCR (Institut des Sciences Chimiques de Rennes)—UMR 6226, University Rennes, F-35000 Rennes, France;
[email protected] 4 Inrae, Inserm, Institut NUMECAN (Nutrition, Métabolismes et Cancer)—UMR_A 1341, University Rennes, UMR_S 1241, F-35033 Rennes, France * Correspondence:
[email protected]; Tel.: +33-029-925-3144 Abstract: Hepatocellular carcinoma (HCC), the most common form of primary liver tumors, is the fifth cancer in the world in terms of incidence, and third in terms of mortality. Despite significant advances in the treatment of HCC, its prognosis remains bleak. Transarterial radioembolization with radiolabeled microspheres and Lipiodol has demonstrated significant effectiveness. Here we present a new, simple radiolabeling of Lipiodol with Yttrium-90, for the potential treatment of HCC. Keywords: hepatocellular carcinoma; hinokitiol; lipiodol; radionuclide therapy; yttrium-90 Citation: Bouvry, C.; Ardisson, V.; Noiret, N.; Garin, E.; Lepareur, N. 1. Introduction Labeling of Hinokitiol with 90Y for Liver tumors, either primary or metastatic, are a leading cause of death throughout Potential Radionuclide Therapy of the world. Primary liver cancers rank third in cancer-related deaths, behind lung and Hepatocellular Carcinoma.